Sharekhan

Akums Drugs and Pharmaceuticals Ltd

Fri 15/05/2026,15:58:15 | NSE : AKUMS

₹ 516.95-10.95 (-2.07%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 531.70

Previous Close

₹ 527.90

Volume

387826

Mkt Cap ( Rs. Cr)

₹8136.48

High

₹ 532.30

Low

₹ 500.05

52 Week High

₹ 622.95

52 Week Low

₹ 409.30

Book Value Per Share

₹ 204.41

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

76.32%

Hold

13.16%

Sell

10.53%

76.32%

38 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

516.95

4

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

4

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs&Pharma. - Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

    16 May 2026, 2:36PM Update on Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Copy of Newspaper Publication

    15 May 2026, 4:43PM Intimation regarding Newspaper Publication
  • Akums Drugs&Pharma. - Investor Presentation

    14 May 2026, 5:36PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
  • Akums Drugs&Pharma. - Monitoring Agency Report

    14 May 2026, 5:17PM Monitoring Agency Report for the quarter ended 31st March, 2026
  • Akums Drugs&Pharma. - Press Release

    14 May 2026, 4:33PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled ""Press Release"".
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 4:20PM Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Record Date

    14 May 2026, 2:27PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 03-Jul-2026.
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:13PM Changes in Senior Management Personnel
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:02PM Appointment of Internal Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:00PM Re-appointment of Cost Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 1:54PM Financial Results for the quarter and year ended 31st March, 2026
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 1:43PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Recommendation of final cum special dividend
  • Akums Drugs&Pharma. - Outcome of Board Meeting

    14 May 2026, 1:34PM Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    14 May 2026, 5:32PM Investor Presentation
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    14 May 2026, 5:20PM Monitoring Agency Report for the quarter ended on 31st March, 2026
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    14 May 2026, 4:35PM Press Release
  • Akums Drugs&Pharma. - Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

    14 May 2026, 4:23PM Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Corporate Action-Board approves Dividend

    14 May 2026, 2:18PM The Board has fixed Friday, July 03, 2026, as the \Record Date\ to ascertain the eligibility of the shareholders for the payment of final cum special
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:10PM Changes in Senior Management Personnel
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:07PM Appointment of Internal Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:05PM Re-appointment of Cost Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Financial Results For The Quarter And Year Ended 31St March, 2026

    14 May 2026, 1:52PM Financial Results for the quarter and year ended 31st March, 2026
  • Akums Drugs&Pharma. Q4 net profit down 44.91% at Rs 15.20 cr

    14 May 2026, 1:50PM The company reported standalone net profit of Rs 15.20 crore for the quarter ended March 31, 2026 as compared to Rs 27.59 crore in the same period las
  • Akums Drugs&Pharma. - Recommendation Of Final Cum Special Dividend

    14 May 2026, 1:46PM Recommendation of Final cum Special Dividend
  • Akums Drugs&Pharma. - Board Meeting Outcome for Outcome Of Board Meeting For Financial Results

    14 May 2026, 1:39PM Outcome of Board meeting for Financial Results
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    12 May 2026, 8:50PM Intimation of Schedule of the Analysts Conference Call for Q4 results and audited financials for FY2026
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    12 May 2026, 8:46PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Board Meeting Intimation for Board Meeting Intimation

    11 May 2026, 11:10PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia,
  • Akums Drugs&Pharma. - ESG Rating

    8 May 2026, 2:51PM Intimation of ESG Rating
  • Akums Drugs&Pharma. - General Updates

    8 May 2026, 2:48PM ESG Rating
  • Akums Drugs&Pharma. - General Updates

    29 Apr 2026, 6:11PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about General Updates
  • Akums Drugs&Pharma. - Execution Of Lease Deed

    29 Apr 2026, 5:49PM Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company has executed a lease deed to purchase an Industrial plot.
  • Akums Drugs&Pharma. - Credit Rating

    11 Apr 2026, 5:41PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Credit Rating
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Credit Rating

    11 Apr 2026, 5:36PM Intimation of reaffirmed/ new credit rating under Reg 30 of SEBI (LODR) Regulations, 2015
  • Akums Drugs&Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    7 Apr 2026, 6:00PM As of March 2026, 75.26% is owned by Indian Promoters, 22.01% by Public and 2.73% by Non Promoters-Non Public. <p align=justify> Institutional holds 1
  • Akums Drugs&Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    4 Apr 2026, 1:02PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    4 Apr 2026, 1:04PM Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
  • Akums Drugs&Pharma. - Disclosure under SEBI Takeover Regulations

    2 Apr 2026, 7:31PM Akums Drugs and Pharmaceuticals Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board
  • Akums Drugs&Pharma. - Trading Window

    23 Mar 2026, 12:56PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Feb 2026, 12:50PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Feb 2026, 12:48PM Bharat Connect Conference
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    19 Feb 2026, 10:30AM Earnings Call Transcript
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    19 Feb 2026, 10:30AM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    19 Feb 2026, 10:18AM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24
Assets 2441.119 2309.177 370.164
Liabilities 2441.119 2309.177 370.164
Equity 30.621 30.621 28.613
Gross Profit 97.46 138.499 -126.658
Net Profit 111.64 160.998 -165.451
Cash From Operating Activities -1.994 91.002 247.907
NPM(%) 8.27 12.27 -11.45
Revenue 1348.736 1311.784 1444.119
Expenses 1251.276 1173.285 1570.777
ROE(%) 3.47 5 -5.14

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1 50 0 516.95

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 720.85 2.41 0.00 295.26 -26.19 0.69
Lotus Eye Hospital and Institute Ltd 106.56 -4.06 343.74 1075.90 3.55 0.00
Vaishali Pharma Ltd 7.07 1.73 0.00 6749.46 3.13 0.00
Astec Lifesciences Ltd 675.80 2.83 0.00 1014.60 -363.15 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Read More

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ

The current price of Akums Drugs and Pharmaceuticals Ltd is ₹ 516.95.

The 52-week high for Akums Drugs and Pharmaceuticals Ltd is ₹ 532.30 and the 52-week low is ₹ 500.05.

The market capitalization of Akums Drugs and Pharmaceuticals Ltd is currently ₹ 8136.48. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Akums Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Akums Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Akums Drugs and Pharmaceuticals Ltd shares.

The CEO of Akums Drugs and Pharmaceuticals Ltd is Mr.Sanjeev Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT